Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down on Insider Selling

Dyne Therapeutics, Inc. (NASDAQ:DYN)’s stock price gapped down prior to trading on Tuesday following insider selling activity. The stock had previously closed at $24.28, but opened at $17.08. Dyne Therapeutics shares last traded at $18.69, with a volume of 2,729,682 shares changing hands.

Specifically, CEO John Cox sold 5,658 shares of the firm’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $18.88, for a total value of $106,823.04. Following the sale, the chief executive officer directly owned 357,507 shares in the company, valued at $6,749,732.16. This trade represents a 1.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Douglas Kerr sold 3,745 shares of Dyne Therapeutics stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $24.35, for a total value of $91,190.75. Following the sale, the insider directly owned 163,854 shares of the company’s stock, valued at $3,989,844.90. This trade represents a 2.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on DYN. Cantor Fitzgerald started coverage on shares of Dyne Therapeutics in a research note on Thursday, July 23rd. They issued an “overweight” rating for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Friday, July 17th. Evercore set a $33.00 target price on Dyne Therapeutics in a report on Friday, May 15th. TD Cowen started coverage on Dyne Therapeutics in a research report on Friday, June 26th. They issued a “buy” rating for the company. Finally, HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Dyne Therapeutics in a research note on Monday, August 17th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $32.17.

Dyne Therapeutics News Summary

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Royal Bank of Canada maintained an “outperform” rating, although it reduced its price target from $35 to $30. RBC said Dyne’s DYNE-101, or z-basivarsen, has important differences from Novartis’ program that could support better outcomes. RBC analysis of Dyne’s DM1 approach
• Positive Sentiment: Dyne is scheduled to present six- and 12-month ACHIEVE trial data for z-basivarsen at the World Muscle Society and AANEM meetings beginning September 29-30. The company expects topline results from its fully enrolled registrational expansion cohort in the first quarter of 2027. Dyne ACHIEVE data announcement
• Neutral Sentiment: JPMorgan downgraded DYN from “neutral” to “underweight” and cut its price target from $17 to $10, while RBC remained bullish. The sharply conflicting views highlight significant uncertainty ahead of Dyne’s clinical updates. JPMorgan downgrade report
• Neutral Sentiment: Call-option activity increased dramatically, with traders purchasing more than 20,000 calls versus an average of roughly 464. This may indicate speculative expectations for a rebound or favorable clinical data, but it does not establish a fundamental improvement.
• Negative Sentiment: Investors appear to be treating the Novartis Phase 3 failure as a warning for the DM1 drug class, causing a sharp decline in Dyne shares despite the company’s upcoming data. Report on rival DM1 trial failure
• Negative Sentiment: Several insiders, including CEO John Cox, reported stock sales. The filings state that the sales were made to cover tax withholding on vested equity awards, reducing their negative significance, but the cluster may add to cautious sentiment.

Dyne Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02. The firm has a market capitalization of $3.58 billion, a price-to-earnings ratio of -5.76 and a beta of 1.08. The firm’s fifty day moving average is $24.77 and its 200 day moving average is $20.52.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). On average, analysts predict that Dyne Therapeutics, Inc. will post -3.47 EPS for the current fiscal year.

Hedge Funds Weigh In On Dyne Therapeutics

Several large investors have recently modified their holdings of DYN. Hilton Head Capital Partners LLC bought a new stake in shares of Dyne Therapeutics in the 1st quarter worth $26,000. Strs Ohio bought a new position in shares of Dyne Therapeutics during the fourth quarter valued at about $51,000. Allworth Financial LP purchased a new position in Dyne Therapeutics during the second quarter worth about $62,000. Aster Capital Management DIFC Ltd purchased a new position in Dyne Therapeutics during the fourth quarter worth about $84,000. Finally, Steward Partners Investment Advisory LLC boosted its holdings in Dyne Therapeutics by 102.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after purchasing an additional 2,465 shares during the last quarter. 96.68% of the stock is owned by institutional investors.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.